The Cognitive and Behavioural Effects of Perampanel in Children with Neurodevelopmental Disorders: A Systematic Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 23

PMID 38256507

Authors

Giovanna Scorrano

Simona Lattanzi

Vincenzo Salpietro

Cosimo Giannini

Francesco Chiarelli

Sara Matricardi

Affiliations

Soon will be listed here.

Abstract

In children and adolescents with epilepsy, neurodevelopmental comorbidities can impair the quality of life more than seizures. The aim of this review was to evaluate the cognitive and behavioural effects of perampanel (PER) in the paediatric population. We performed a systematic search of the literature, selecting studies published in English including children and adolescents with epilepsy treated with PER. Cognitive and behavioural outcomes were assessed through validated neuropsychological standardised scales. Eighteen studies involving 3563 paediatric patients were included. Perampanel did not impair general cognitive functions and visuospatial skills, whereas a slight improvement in verbal memory and a decline in attentional power were detected. In adolescents with refractory epilepsies, high doses and/or rapid titration of PER and an underlying psychiatric disorder were risk factors for developing or worsening psychiatric outcomes such as anger, aggressiveness, and irritability. Data on children and adolescents treated with new antiseizure medications are scant, and neuropsychiatric effects are tricky to be detected during developmental age. According to the currently available evidence, PER showed an overall favourable risk-benefit profile. Pharmacodynamics, co-administration of other antiseizure medications, and family and personal history of neuropsychiatric disorders should be considered before PER treatment.

References

Fong Y, Huang P, Hsu C, Yang Y . Effects of Perampanel on Seizure Control, Cognition, Behavior, and Psychological Status in Patients With Epilepsy: A Systematic Review. J Clin Neurol. 2022; 18(6):653-662. PMC: 9669553. DOI: 10.3988/jcn.2022.18.6.653. View

Fattorusso A, Matricardi S, Mencaroni E, DellIsola G, Di Cara G, Striano P . The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies. Front Neurol. 2021; 12:674483. PMC: 8258148. DOI: 10.3389/fneur.2021.674483. View

Perversi F, Costa C, Labate A, Lattanzi S, Liguori C, Maschio M . The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol. 2023; 14:1182304. PMC: 10359664. DOI: 10.3389/fneur.2023.1182304. View

Hansen C, Ljung H, Brodtkorb E, Reimers A . Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. Behav Neurol. 2018; 2018:2064027. PMC: 6276511. DOI: 10.1155/2018/2064027. View

Mammi A, Ferlazzo E, Gasparini S, Bova V, Neri S, Labate A . Psychiatric and Behavioural Side Effects Associated With Perampanel in Patients With Temporal Lobe Epilepsy. A Real-World Experience. Front Neurol. 2022; 13:839985. PMC: 8936072. DOI: 10.3389/fneur.2022.839985. View

Lee S, Jeon J, Kim H . Effect of perampanel on aggression in patients with refractory focal epilepsy: A 6-month longitudinal study. Epilepsy Behav. 2019; 102:106658. DOI: 10.1016/j.yebeh.2019.106658. View

Snoeijen-Schouwenaars F, van Ool J, Tan I, Schelhaas H, Majoie M . Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav. 2016; 66:64-67. DOI: 10.1016/j.yebeh.2016.10.013. View

Verrotti A, Moavero R, Panzarino G, Di Paolantonio C, Rizzo R, Curatolo P . The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity. Clin Drug Investig. 2017; 38(1):1-8. DOI: 10.1007/s40261-017-0585-1. View

Pina-Garza J, Lagae L, Villanueva V, Renfroe J, Laurenza A, Williams B . Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018; 83:50-58. DOI: 10.1016/j.yebeh.2018.03.029. View

10.

Rohracher A, Zimmermann G, Villanueva V, Garamendi I, Sander J, Wehner T . Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia. 2018; 59(9):1727-1739. DOI: 10.1111/epi.14520. View

11.

Santamarina E, Bertol V, Garayoa V, Garcia-Gomara M, Garamendi-Ruiz I, Giner P . Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs. Seizure. 2020; 83:48-56. DOI: 10.1016/j.seizure.2020.09.026. View

12.

Dolton E, Choudry A . Perampanel and challenging behaviour in intellectual disability and epilepsy: a management dilemma. Case Rep Psychiatry. 2015; 2014:409209. PMC: 4280655. DOI: 10.1155/2014/409209. View

13.

Auvin S . Paediatric epilepsy and cognition. Dev Med Child Neurol. 2022; 64(12):1444-1452. DOI: 10.1111/dmcn.15337. View

14.

Auvin S, Dozieres B, Ilea A, Delanoe C . Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav. 2017; 74:59-63. DOI: 10.1016/j.yebeh.2017.05.036. View

15.

Majid O, Laurenza A, Ferry J, Hussein Z . Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016; 82(2):422-30. PMC: 4972158. DOI: 10.1111/bcp.12951. View

16.

Goji H, Kanemoto K . The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study. Seizure. 2019; 67:1-4. DOI: 10.1016/j.seizure.2019.02.009. View

17.

Lagae L, Villanueva V, Meador K, Bagul M, Laurenza A, Kumar D . Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016; 57(7):1120-9. DOI: 10.1111/epi.13417. View

18.

Lin K, Lin J, Chou M, Hung P, Hsieh M, Chou I . Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav. 2018; 85:188-194. DOI: 10.1016/j.yebeh.2018.06.033. View

19.

Wang Y, Chen Z . An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy. Pharmacol Ther. 2019; 201:77-93. DOI: 10.1016/j.pharmthera.2019.05.010. View

20.

Fogarasi A, Flamini R, Milh M, Phillips S, Yoshitomi S, Patten A . Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia. 2020; 61(1):125-137. PMC: 7004020. DOI: 10.1111/epi.16413. View